Gonadotrophin Releasing Hormone Agonist Addition for Luteal Support in In-vitro Fertilization and Embryo Transfer Cycles

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02908438

Enrollment

400

Registered

2016-09-21

Start date

2016-09-30

Completion date

Unknown

Last updated

2016-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GnRHa;LPS

Brief summary

The study was designed to investigate the effect of luteal-phase administration of gonadotrophin releasing hormone agonist(GnRHa) on pregnancy outcomes in in-vitro fertilization-embryo transfer.

Interventions

DRUGGonadotrophin releasing hormone agonist(GnRHa)

GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 37 Years

Healthy volunteers

Inclusion criteria

1. Age \< 37 years; 2. One or more high quality embryos have been got in IVF/ICSI treatment; 3. To transfer at lest 2 fresh embryos; 4. Uterine endometrial thickness ≥ 7mm; 5. Patients have signed informed consents.

Exclusion criteria

1. ≥3 IVF/ICSI/FET cycles and no pregnancy; 2. Polycystic ovary syndrome(PCOS); 3. uterine malformation; 4. endometriosis 5. patients with a history of recurrent pregnancy loss.

Design outcomes

Primary

Measure	Time frame
pregnancy rate	up to 12 months

Contacts

Primary ContactShan Liu, PHD

123564787@qq.com86+18991932450

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026